WHWinni De Haes

Winni De Haes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Winni De Haes has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lipoplexes Carrying mRNA Encoding Gag Protein Modulate Dendritic Cells to Stimulate HIV-Specific Immune Responses

    by Winni De Haes, Joanna Rejman, Charlotte Pollard, Céline Merlin, Marc Vekemans, Eric Florence, Stefaan C De Smedt, Johan Grooten, Guido Vanham, Stefaan De Koker, et al.

    Cationic lipids (Lipofectamine™ [Invitrogen, Merelbeke, Belgium] and 1,2-dioleoyl-3-trimethylammonium-propane/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) and polymers (jetPEI™ and in vivo-jetPEI™ [Polyplus-transfection, Illkirch, France]) were evaluated for their potential to deliver mRNA to monocyte-derived dendritic cells. Lipoplexes and polyplexes, containing mRNA encoding GFP or Gag protein, were incubated with human monocyte-derived dendritic cells and transfection efficiencies were assessed by flow cytometry. Lipofectamine was by far the most efficient in mRNA delivery, therefore it was used in further experiments. Incubation of monocyte-derived dendritic cells isolated from HIV-1-positive donors with mRNA encoding Gag protein complexed to Lipofectamine resulted in 50% transfection. Importantly, coculture of these Gag-transfected dendritic cells with autologous T cells induced an over tenfold expansion of IFN-γ- and IL-2-secreting CD4(+) and CD8(+) T cells. Cationic lipid-mediated mRNA delivery may be a useful tool for therapeutic vaccination against HIV-1. This approach can be applied to develop vaccination strategies for other infectious diseases and cancer.


  • Internalization of mRNA Lipoplexes by Dendritic Cells

    by Winni De Haes, Greet Van Mol, Céline Merlin, Stefaan C. De Smedt, Guido Vanham, Joanna Rejman

    Lipoplexes, composed of Lipofectamine and mRNA encoding HIV Gag protein, were shown to be internalized by dendritic cells (DCs) and promote antigen presentation to stimulate HIV-specific T cell responses. Using confocal microscopy, we showed that one-third of fluorescently labeled mRNA containing lipoplexes are colocalized with late endosomes. We further investigated the effect of inhibitors, blocking phagocytosis, macropinocytosis, and clathrin- and caveolae-mediated endocytosis, on both the internalization of the lipoplexes by DCs and the transfection efficiency. We observed that chloropromazine had no effect on the cellular uptake or transfection efficiency, excluding the involvement of clathrin-mediated endocytosis. Cytochalasin D, inhibiting macropinocytosis and phagocystosis, strongly reduced internalization (50%) of the lipoplexes as well as protein expression (70%). Amiloride, which should specifically block macropinocytosis, induced only a modest reduction of uptake and transfection. Genistein and dynasore induced a strong reduction of on the level of protein expression (>70%), but not the overall uptake. Our results indicate that transfection-effective mRNA lipoplex internalization by DCs, i.e., uptake that results in protein expression, preferentially proceeds by macropinocytosis and/or phagocytosis.


  • Open Access

    Erratum to: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

    by Britta Wahren, Priscilla Biswas, Marie Borggren, Adam Coleman, Kelly Da Costa, Winni De Haes, Tessa Dieltjens, Stefania Dispinseri, Katrijn Grupping, David Hallengärd, et al.

  • Open Access

    Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

    by Britta Wahren, Priscilla Biswas, Marie Borggren, Adam Coleman, Kelly Da Costa, Winni De Haes, Tessa Dieltjens, Stefania Dispinseri, Katrijn Grupping, David Hallengärd, et al.

    EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research program in the field of HIV vaccines and microbicides to training, dissemination and advocacy. The research program covers the whole pipeline of vaccine and microbicide development from discovery to early clinical trials. The Network is composed of 58 partners representing more than 65 institutions from 13 European countries; it also includes three major pharmaceutical companies (GlaxoSmithKline, Novartis and Sanofi-Pasteur) involved in HIV microbicide and vaccine research. The Network displays a dedicated and informative web page: http://www.europrise.org. Finally, a distinguishing trait of EUROPRISE is its PhD School of students from across Europe, a unique example in the world of science aimed at spreading excellence through training. EUROPRISE held its second annual conference in Budapest in November, 2009. The conference had 143 participants and their presentations covered aspects of vaccine and microbicide research, development and discovery. Since training is a major task of the Network, the students of the EUROPRISE PhD program summarized certain presentations and their view of the conference in this paper.


  • Open Access

    Polyelectrolyte Capsules-containing HIV-1 p24 and Poly I:C Modulate Dendritic Cells to Stimulate HIV-1-specific Immune Responses

    by Winni De Haes, Stefaan De Koker, Charlotte Pollard, Derek Atkinson, Erika Vlieghe, Jessy Hoste, Joanna Rejman, Stefaan De Smedt, Johan Grooten, Guido Vanham, et al.